Navigation Links
GeneThera, Inc. Acquires Applied Genetics, S.A.
Date:1/25/2012

WESTMINSTER, Colo., Jan. 25, 2012 /PRNewswire/ -- GeneThera, Inc. (OTCQB: GTHR) announced today that it has acquired a majority ownership of Applied Genetics, a molecular diagnostic company based in Monterrey, Mexico. Applied Genetics is a molecular diagnostic company that focuses on commercializing molecular testing for Johne's disease in Mexico.

This acquisition is part of a broader strategy aimed at quickly initiating Applied Genetics revenue-generating operation.

Dr. Tony Milici, CEO of GeneThera and Interim President of Applied Genetics, commented on the news: "We are very pleased to have reached an agreement with the other shareholders of Applied Genetics to acquire a controlling interest in the company. We will continue our efforts to make GeneThera a leader in molecular diagnostic testing both in Mexico and South America."

Johne's disease is a global devastating and incurable disease of dairy cows, sheep, and goats caused by a bacterium called Mycobacterium Paratuberculosis sub. Avium, (MAP).   An overwhelming number of studies have shown that MAP is the causative agent of Crohn's disease in humans. Dairy products, contaminated with MAP, are the vehicles by which the infection spreads in the human intestine. Applied Genetics employs the use of GeneThera HerdCheck™ to test and control the spread of Johne's disease in Mexico.  HerdCheck™ is a proprietary molecular diagnostic system based on the use of high throughput robotics and Real time PCR.

About GeneThera, Inc.
GeneThera, Inc. is a molecular biotechnology company located in Westminster, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES™ and Johne's disease management system, HERDCHECK™, designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES™ and HERDCHECK™ systems are designed for a host of individual diseases, the current priority being Johne's disease.

This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "intends," "believes," and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.

For more information, contact Dr. Tony Milici at 720- 439-3011. http://www.genethera.net

GeneThera, Inc.


'/>"/>
SOURCE GeneThera, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. [video] Dr. Tony Milici, Chairman and CEO of GeneThera, Inc., Discusses Worldwide Rights to E.Coli Vaccine on WallSt.nets 3-Minute Press Show
2. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
3. Safecor Health Acquires Unit-Dose Pharmaceutical Leader RSC
4. Arisyn Therapeutics Inc. Acquires Highly Novel Portfolio of Therapeutic Small Molecules for Infectious Disease and Cancer
5. MediCult Acquires US-Based MidAtlantic Diagnostics to Further Strengthen ART Presence
6. Milestone Scientific Acquires Additional Patent Rights for Painless Injections and Resolves Related Litigations
7. Advanced Instruments Acquires D & F Control Systems Inc.
8. Circassia Acquires North American and Japanese Rights to Dopexamine
9. CPA Acquires Renowned German Patent Research Specialist, SVPG
10. Millstone Medical Outsourcing Acquires New Facility to Accommodate Growing Business, Provide Additional Clean Room Capacity
11. Affitech Acquires Pharmexas Diabody Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , ... October 12, 2017 ... ... has launched Rosalindâ„¢, the first-ever genomics analysis platform specifically designed for life ... Named in honor of pioneering researcher Rosalind Franklin, who made a major ...
(Date:10/11/2017)... Wayne. NJ (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a ... rinse one eye at a time. So which eye do you rinse first if a ... you have Plum Duo Eye Wash with its unique dual eye piece. , ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... A new study published ... frozen and fresh in vitro fertilization (IVF) transfer cycles. The multi-center ... success. , After comparing the results from the fresh and frozen transfer cohorts, ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... 5, 2017  The Allen Institute for Cell Science ... a one-of-a-kind portal and dynamic digital window into the ... the first application of deep learning to create predictive ... lines and a growing suite of powerful tools. The ... and future publicly available resources created and shared by ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):